JP2024532294A - Ｍｃ４ｒアゴニストペプチド - Google Patents

Ｍｃ４ｒアゴニストペプチド Download PDF

Info

Publication number
JP2024532294A
JP2024532294A JP2024512103A JP2024512103A JP2024532294A JP 2024532294 A JP2024532294 A JP 2024532294A JP 2024512103 A JP2024512103 A JP 2024512103A JP 2024512103 A JP2024512103 A JP 2024512103A JP 2024532294 A JP2024532294 A JP 2024532294A
Authority
JP
Japan
Prior art keywords
phe
arg
cys
peptide
trp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024512103A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024532294A5 (https=
Inventor
ワイ． ウィリアムス，サバンナ
イー． ヒメネス，ルイス
ソーヤー，トミ
ディー． コーン，ロジャー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
University of Michigan Ann Arbor
Original Assignee
University of Michigan System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System filed Critical University of Michigan System
Publication of JP2024532294A publication Critical patent/JP2024532294A/ja
Publication of JP2024532294A5 publication Critical patent/JP2024532294A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2024512103A 2021-08-24 2022-08-24 Ｍｃ４ｒアゴニストペプチド Pending JP2024532294A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163236485P 2021-08-24 2021-08-24
US63/236,485 2021-08-24
PCT/US2022/075425 WO2023028538A1 (en) 2021-08-24 2022-08-24 Mc4r agonist peptides

Publications (2)

Publication Number Publication Date
JP2024532294A true JP2024532294A (ja) 2024-09-05
JP2024532294A5 JP2024532294A5 (https=) 2025-09-02

Family

ID=85322183

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024512103A Pending JP2024532294A (ja) 2021-08-24 2022-08-24 Ｍｃ４ｒアゴニストペプチド

Country Status (4)

Country Link
US (1) US20240391954A1 (https=)
EP (1) EP4392072A4 (https=)
JP (1) JP2024532294A (https=)
WO (1) WO2023028538A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114478694A (zh) * 2020-11-13 2022-05-13 成都奥达生物科技有限公司 一种长效mc4r激动剂
WO2025042770A1 (en) * 2023-08-18 2025-02-27 The Regents Of The University Of Michigan Anorexia-sensitizing agents
CN120192363A (zh) * 2023-12-22 2025-06-24 上海多米瑞生物技术有限公司 多肽化合物、其药物组合物及其用途
WO2025254700A1 (en) * 2024-06-05 2025-12-11 Endevica Bio, Inc. Orally deliverable non-naturally occurring melanocortin analogs
CN120699097A (zh) * 2024-09-03 2025-09-26 万邦德制药集团有限公司 一种二硫环肽化合物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009500426A (ja) * 2005-07-08 2009-01-08 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス メラノコルチン受容体のリガンド
CN115957297A (zh) * 2013-03-15 2023-04-14 节奏制药公司 药物组合物
EP2970388B1 (en) * 2013-03-15 2018-07-25 Rhythm Pharmaceuticals, Inc. Peptide compositions
PL3356386T3 (pl) * 2015-09-30 2024-08-05 Rhythm Pharmaceuticals, Inc. Sposób leczenia zaburzeń związanych ze szlakiem receptora melanokortyny 4
US20210179666A1 (en) * 2019-12-09 2021-06-17 Regents Of The University Of Minnesota Cyclic peptides and methods of use thereof

Also Published As

Publication number Publication date
EP4392072A1 (en) 2024-07-03
EP4392072A4 (en) 2026-03-04
US20240391954A1 (en) 2024-11-28
WO2023028538A1 (en) 2023-03-02

Similar Documents

Publication Publication Date Title
US20240391954A1 (en) Mc4r agonist peptides
KR102351313B1 (ko) Gip/glp1 공효능제 화합물
US8883721B2 (en) Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
Calo' et al. Pharmacology of nociceptin and its receptor: a novel therapeutic target
JP4275852B2 (ja) カッパ受容体オピオイドペプチド
US8536120B2 (en) Ghrelin/growth hormone releasing peptide/growth hormone secretatogue receptor antagonists and uses thereof
EP2329839B1 (en) Modification of feeding behavior by GLP-1 and PYY
RU2381233C2 (ru) Агонисты рецептора меланокортина
US20090227519A1 (en) Compounds for control of appetite
EP0707490A1 (en) Neuropeptide y antagonists and agonists
US20220313789A1 (en) Targeting melanocortin 3 receptor for treatment/prevention of eating, metabolism, and/or emotional disorders
JP2007531713A6 (ja) 治療的介入のためのｙ２選択性レセプターアゴニスト
JP2007531713A (ja) 治療的介入のためのｙ２選択性レセプターアゴニスト
US20260098072A1 (en) Methods of stimulating appetite and/or increasing body weight using non-naturally occurring melanocortin receptor antagonist analogs
US7851588B2 (en) CRFR1 selective ligands
US20240287154A1 (en) Mc3r agonist peptides
AU2002232903B2 (en) Urotensin-II agonists and antagonists
US9724381B2 (en) Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
WO2025123056A1 (en) Non-naturally occurring melanocortin analogs and associated methods
AU2005202153A1 (en) Urotensin-II agonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250825

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250825